Peptide library / Immune & defense / Nangibotide
Nangibotide
A TREM-1 inhibitor peptide tested in septic shock.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Septic shockSmall human studies
How it is thought to work
Nangibotide blocks TREM-1, a receptor that amplifies inflammation in severe infection.
What the evidence shows
A phase 2b trial did not meet its main goal overall but suggested benefit in patients with high TREM-1 activity.
Safety and unknowns
Similar to placebo in trials.
Regulatory status
Not approved. Further trials are planned.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Immune & defense
Oritavancin
FDA-approvedA long-acting lipoglycopeptide antibiotic given as a single infusion.
Pexiganan
In clinical trialsA magainin-like peptide cream tested for infected diabetic foot ulcers.
Murepavadin
In clinical trialsA first-in-class peptide antibiotic targeting Pseudomonas aeruginosa.
General information, not medical advice. Do not buy or inject unregulated peptides.